Hosted on MSN18d
Pyxis Oncology rises on FDA fast track tag for lead asset
An antibody-drug conjugate, PYX-201, is currently undergoing two clinical trials, PYX-201-101 and PYX-201-102, designed to test it as a single agent and in combination with Merck’s anti-PD-1 ...
Hosted on MSN17d
FDA grants fast track status to Pyxis’ PYX-201
The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC), PYX-201, to treat adults with recurrent or metastatic head and ...
Yahoo Finance19d
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
PYX-201 is a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM ...
Nasdaq18d
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology, Inc. announced that the FDA has granted Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell ...
Repubblica20d
Vini dealcolati, cresce il mercato. A Vinitaly il debutto
Il direttore generale di Veronafiere, Adolfo Rebughini, ha spiegato che «l’obiettivo è di rappresentare un mercato complementare ai vini di denominazione in forte crescita su scala globale».